Clinical trials: Healthy Human Volunteers
- Condition Healthy Human Volunteers
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Intervention for Nerve Agent Exposure
First Time in Human Study of Protexia
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of Protexia, an experimental drug being developed to protect soldiers against the effects of nerve agents.
- Trial name
- NCT00744146
- Testing
- Protexia
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- PharmAthene, Inc.
Healthy Volunteers
Spire Health Remote Patient Monitor Human Factors Summative Study Protocol
This usability validation testing protocol outlines the methods being used to demonstrate and gather evidence that the current design and user experience of the Spire Remote Patient Monitor are safe and effective for use by the…
- Trial name
- NCT06395350
- Testing
- Spire Health Monitor
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Spire, Inc.
NASH
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.
A non-randomized, multiple-dose, open-label, single sequence study to evaluate effect of concomitant administration of EDP-305 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy human…
- Trial name
- NCT03187496
- Testing
- Midazolam, Caffeine, Rosuvastatin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Influenza (Healthy Volunteers)
Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea
To describe the immune response induced by quadrivalent recombinant influenza vaccine (RIV4) and Quadrivalent-inactivated Influenza Vaccine (IIV4) in 18-49 and greater than or equal to (>=) 50 years of age participants by…
- Trial name
- NCT05144945
- Testing
- Quadrivalent Recombinant Influenza Vaccine (RIV4), Quadrivalent inactivated influenza vaccine (IIV4)
- Where
- 3 sites in South Korea
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day washout between treatments.
- Trial name
- NCT01353729
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects
This is a single dose study of radiolabeled [14C]-LY2452473 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY2452473.
- Trial name
- NCT01275157
- Testing
- LY2452473
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A First-in-human Trial to Assess the Safety and Performance of the BioCaptis in Healthy Volunteers
Liquid biopsy is a new field in medicine where doctors can look at small molecules in our blood, called DNA, that carry the genetic material that makes us who we are.
- Trial name
- NCT05813041
- Testing
- BioCaptis
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BioCaptiva Ltd.
Safety Issues
A Phase I Clinical Study of Hemay808
This is a first-in-human study in health volunteers. The purpose is the local tolerability and systemic safety of Hemay808, which is an ointment made of a novel small molecule Hemay028.
- Trial name
- NCT04100642
- Testing
- Hemay808
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Hereditary Angioedema
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
This is a 3-part Phase 1 dose-ranging study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single (Part 1) and multiple (Part 2) ascending doses of BCX7353 in healthy subjects, and single and…
- Trial name
- NCT02448264
- Testing
- BCX7353
- Where
- United Kingdom
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants
- Trial name
- NCT07422207
- Testing
- ME3241
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Meiji Pharma USA Inc.
Healthy
A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers
The purposes of this study were: To evaluate the plasma pharmacokinetic profile of tramadol and its principal metabolite, the O-desmethyltramadol, after a single oral administration of 100, 200 and 300 mg of tramadol as the…
- Trial name
- NCT00834808
- Testing
- Tramadol HCl
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Labopharm Inc.
Influenza
A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population
The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.
- Trial name
- NCT01113580
- Testing
- CSL's 2010/2011 Formulation of Enzira® Vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Healthy Volunteers - Male and Female
A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary characteristics of the investigational drug QLS7305 in healthy adult participants in China.
- Trial name
- NCT07313150
- Testing
- QLS7305 Injection
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy Volunteers, Propionic Acidemia
A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia
The purpose of this study is to assess the safety, tolerability, PK and PD of BBP-671 in healthy volunteers and patients with Propionic Acidemia or Methylmalonic Acidemia.
- Conditions
- Healthy Volunteers, Propionic Acidemia, Methylmalonic Acidemia, Organic Acidemia
- Trial name
- NCT04836494
- Testing
- BBP-671
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- CoA Therapeutics, Inc., a BridgeBio company
Atopic Dermatitis
A First-in-Human Study of CEE321 in Adult Subjects
Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis
- Trial name
- NCT04612062
- Testing
- CEE321
- Where
- 3 sites in United States, Japan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
A First-time-in-human Study of BGB149
This clinical trial is a Phase I, first-in-human. The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of BGB149 after single IV doses in healthy male and…
- Trial name
- NCT03795142
- Testing
- BGB149
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Human Immunodeficiency Virus Infection
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.
- Trial name
- NCT05141422
- Testing
- SHR2150 tablet、efavirenz
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatitis C Virus
TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin
The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the single-dose pharmacokinetics of digoxin or rosuvastatin , and the effect of a single dose of digoxin or rosuvastatin on the…
- Trial name
- NCT01288742
- Testing
- Rosuvastatin, TMC435, Digoxin
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy Human Volunteers
Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple doses of XPF-001 in healthy volunteers. The effect of food on the pharmacokinetics of XPF-001 will also be studied.
- Trial name
- NCT00813670
- Testing
- XPF-001
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Xenon Pharmaceuticals Inc.
Healthy
Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)
An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Pharmaceutical Industries, Egypt) versus…
- Trial name
- NCT02675127
- Testing
- Daktavira, Daklinza
- Where
- Egypt
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genuine Research Center, Egypt